Real-world study confirms mepolizumab cuts asthma attacks and steroid use
NCT ID NCT05091385
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 106 adults with severe eosinophilic asthma in Poland who received mepolizumab injections every 4 weeks for at least a year. Researchers tracked asthma attacks and the need for oral steroids before and during treatment. The goal was to see if the drug helps control the disease in everyday clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA; EOSINOPHILIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of Lodz, Dept. of Immunology and Allergy
Lodz, 92-213, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
- Smart inhalers track Fasenra's asthma control over full dosing cycle
- CT scan could predict asthma drug success, saving months of trial and error
- New asthma drug shows promise in real-world greek study
- Real-World study checks if benralizumab tames severe asthma in taiwan
- Severe asthma drug may boost daily steps, study hopes